Skip to main content

Abstract 155: Hyperglycemia And Hypertension Predict Subsequent Ischemic Stroke In Patients With Minor Stroke Or TIA Treated With Dual Antiplatelet Therapy: A Post-hoc Analysis Of The POINT Trial

Publication ,  Conference
Kvernland, A; de Havenon, A; Rostanski, S; Mac Grory, B; Goldstein, E; Johnston, C; Easton, JD; Kim, A; Anadani, M; Henninger, N; Liberman, AL ...
Published in: Stroke
February 2022

Randomized trials have shown that dual antiplatelet therapy (DAPT) reduces the risk of subsequent ischemic stroke in patients with minor stroke or high-risk TIA (MS-TIA). However, the 90 day risk remains elevated at 5-8%. In this exploratory study, we aimed to identify predictors of subsequent ischemic stroke in patients with MS-TIA treated with DAPT. This is a post-hoc analysis of the POINT trial that randomized patients with MS-TIA to DAPT versus aspirin monotherapy. For this analysis, we included only patients treated with DAPT and performed univariate and adjusted Cox-regression analyses to determine predictors of subsequent ischemic stroke. We also performed receiver operating analysis to determine predictive accuracy. P<0.05 was considered statistically significant. Among 2,398 MS-TIA patients treated with DAPT, 109 (4.5%) had ischemic stroke during the 90 day follow up interval. In Cox-regression analyses, predictors of subsequent ischemic stroke were admission glucose level per 10 mg/dL increase (adjusted HR 1.04 95% CI 1.03-1.06, p < 0.001), admission blood pressure per 10 mm Hg increase (aHR 1.10 95% CI 1.03-1.17, p = 0.006) and presence of infarct on index imaging (adjusted HR 2.04 95% CI 1.40-2.98, p<0.001). Subsequent stroke risk was particularly increased in patients with serum glucose ≥180 mg/dL (adjusted HR 2.45 95% CI 1.60-3.75, p<0.001) and systolic blood pressure ≥180 mmHg (adjusted HR 1.71 95% CI 1.16-2.52, p = 0.007). The rate of subsequent stroke when both predictors were present was 14.7% and when none was present was 3.3%. Their independent predictive accuracy was modest in receiver operating curves: glucose (AUC = 0.66 95% CI 0.61-0.71) and systolic blood pressure (AUC = 0.60 95% CI 0.54-0.65). Findings were similar in a sensitivity analysis where patients without imaging confirmation of subsequent stroke were excluded. Patients with MS-TIA who have hyperglycemia or hypertension on admission are at a relatively high risk of subsequent ischemic stroke despite DAPT. Future studies are needed to validate our findings and explore whether targeted treatment of these factors can affect short term stroke risk.

Duke Scholars

Published In

Stroke

DOI

EISSN

1524-4628

ISSN

0039-2499

Publication Date

February 2022

Volume

53

Issue

Suppl_1

Publisher

Ovid Technologies (Wolters Kluwer Health)

Related Subject Headings

  • Neurology & Neurosurgery
  • 4201 Allied health and rehabilitation science
  • 3209 Neurosciences
  • 3202 Clinical sciences
  • 1109 Neurosciences
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kvernland, A., de Havenon, A., Rostanski, S., Mac Grory, B., Goldstein, E., Johnston, C., … Yaghi, S. (2022). Abstract 155: Hyperglycemia And Hypertension Predict Subsequent Ischemic Stroke In Patients With Minor Stroke Or TIA Treated With Dual Antiplatelet Therapy: A Post-hoc Analysis Of The POINT Trial. In Stroke (Vol. 53). Ovid Technologies (Wolters Kluwer Health). https://doi.org/10.1161/str.53.suppl_1.155
Kvernland, Alexandra, Adam de Havenon, Sara Rostanski, Brian Mac Grory, Eric Goldstein, Claiborne Johnston, J Donald Easton, et al. “Abstract 155: Hyperglycemia And Hypertension Predict Subsequent Ischemic Stroke In Patients With Minor Stroke Or TIA Treated With Dual Antiplatelet Therapy: A Post-hoc Analysis Of The POINT Trial.” In Stroke, Vol. 53. Ovid Technologies (Wolters Kluwer Health), 2022. https://doi.org/10.1161/str.53.suppl_1.155.
Kvernland A, de Havenon A, Rostanski S, Mac Grory B, Goldstein E, Johnston C, et al. Abstract 155: Hyperglycemia And Hypertension Predict Subsequent Ischemic Stroke In Patients With Minor Stroke Or TIA Treated With Dual Antiplatelet Therapy: A Post-hoc Analysis Of The POINT Trial. In: Stroke. Ovid Technologies (Wolters Kluwer Health); 2022.
Kvernland, Alexandra, et al. “Abstract 155: Hyperglycemia And Hypertension Predict Subsequent Ischemic Stroke In Patients With Minor Stroke Or TIA Treated With Dual Antiplatelet Therapy: A Post-hoc Analysis Of The POINT Trial.” Stroke, vol. 53, no. Suppl_1, Ovid Technologies (Wolters Kluwer Health), 2022. Crossref, doi:10.1161/str.53.suppl_1.155.
Kvernland A, de Havenon A, Rostanski S, Mac Grory B, Goldstein E, Johnston C, Easton JD, Kim A, Anadani M, Henninger N, Liberman AL, Furie KL, Yaghi S. Abstract 155: Hyperglycemia And Hypertension Predict Subsequent Ischemic Stroke In Patients With Minor Stroke Or TIA Treated With Dual Antiplatelet Therapy: A Post-hoc Analysis Of The POINT Trial. Stroke. Ovid Technologies (Wolters Kluwer Health); 2022.

Published In

Stroke

DOI

EISSN

1524-4628

ISSN

0039-2499

Publication Date

February 2022

Volume

53

Issue

Suppl_1

Publisher

Ovid Technologies (Wolters Kluwer Health)

Related Subject Headings

  • Neurology & Neurosurgery
  • 4201 Allied health and rehabilitation science
  • 3209 Neurosciences
  • 3202 Clinical sciences
  • 1109 Neurosciences
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology